03Oct

Amylin, Takeda call off obesity treatment

In CategoryDrugs and Drug Companies, Treatments, Therapy, Recovery, Health Care, Weight Health
ByRuss Bianchi

Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said Thursday that they are discontinuing development of pramlintide/metreleptin, a combination therapy to treat obesity.

Amylin, Takeda call off obesity treatment

Share

Tags: , ,

Comments are closed.